Brokerages expect that Motus GI Holdings Inc (NASDAQ:MOTS) will announce ($0.25) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Motus GI’s earnings, with estimates ranging from ($0.29) to ($0.21). Motus GI reported earnings of ($0.33) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 24.2%. The firm is expected to announce its next earnings results on Wednesday, November 13th.
According to Zacks, analysts expect that Motus GI will report full-year earnings of ($1.05) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($0.95). For the next fiscal year, analysts forecast that the business will report earnings of ($0.92) per share, with EPS estimates ranging from ($1.40) to ($0.73). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Motus GI.
Motus GI (NASDAQ:MOTS) last posted its earnings results on Friday, August 9th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03.
In other Motus GI news, major shareholder Life Sciences Maste Perceptive purchased 1,000,000 shares of the firm’s stock in a transaction dated Thursday, June 27th. The stock was bought at an average cost of $3.00 per share, with a total value of $3,000,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Chairman David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were acquired at an average cost of $3.00 per share, with a total value of $30,000.00. The disclosure for this purchase can be found here. Insiders have bought a total of 2,054,332 shares of company stock valued at $6,162,996 over the last ninety days. Company insiders own 18.14% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. CVI Holdings LLC bought a new position in shares of Motus GI in the second quarter valued at $42,000. Northern Trust Corp bought a new position in shares of Motus GI in the second quarter valued at $52,000. Morgan Stanley grew its stake in shares of Motus GI by 1,333.3% in the second quarter. Morgan Stanley now owns 30,100 shares of the company’s stock valued at $91,000 after buying an additional 28,000 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of Motus GI in the second quarter valued at $107,000. Finally, Spark Investment Management LLC lifted its holdings in Motus GI by 73.5% during the 1st quarter. Spark Investment Management LLC now owns 28,900 shares of the company’s stock valued at $112,000 after purchasing an additional 12,245 shares during the last quarter. 40.33% of the stock is owned by institutional investors and hedge funds.
NASDAQ MOTS traded down $0.05 during trading hours on Friday, reaching $2.69. 96,053 shares of the company’s stock were exchanged, compared to its average volume of 72,937. The company’s 50-day moving average is $2.84 and its two-hundred day moving average is $3.61. Motus GI has a one year low of $2.34 and a one year high of $7.40. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.92 and a quick ratio of 3.89.
About Motus GI
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.